=> d l1
L1 HAS NO ANSWERS
L1 STR



VAR G1=N/HY
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC 8 3
NUMBER OF NODES IS 20

STEREO ATTRIBUTES: NONE

=> s l1 ful
FULL SEARCH INITIATED 16:06:55 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 42901 TO ITERATE

100.0% PROCESSED 42901 ITERATIONS 2 ANSWERS
SEARCH TIME: 00.00.02

L3 2 SEA SSS FUL L1

=> d 1-2

L3 ANSWER 1 OF 2 REGISTRY COPYRIGHT 2003 ACS
RN 468105-70-6 REGISTRY
CN Piperidine, 1-[(5S)-5-amino-6-(1H-imidazol-4-yl)-1,4-dioxohexyl]-4-(1-oxobutyl)-4-phenyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C24 H32 N4 O3
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

L3 ANSWER 2 OF 2 REGISTRY COPYRIGHT 2003 ACS
RN 457894-18-7 REGISTRY
CN Acetamide, N-[(1S)-1-(1H-imidazol-4-ylmethyl)-2,5-dioxo-5-[4-(1-oxobutyl)-4-phenyl-1-piperidinyl]pentyl]- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C26 H34 N4 O4
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

=> fil caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	152.71	152.92

FILE 'CAPLUS' ENTERED AT 16:07:12 ON 21 APR 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 21 Apr 2003 VOL 138 ISS 17
FILE LAST UPDATED: 20 Apr 2003 (20030420/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3
L4 2 L3

=> d bib abs hitstr 1-2

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2003 ACS
AN 2002:777885 CAPLUS
DN 137:295252
TI Preparation of peptides for pharmaceutical use as modulators of melanocortin receptors
IN Yu, Guixue; Macor, John; Herpin, Timothy; Lawrence, R. Michael; Morton, George C.; Ruel, Rejean; Poindexter, Graham S.; Ruediger, Edward H.; Thibault, Carl
PA Bristol-Myers Squibb Company, USA
SO PCT Int. Appl., 116 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002079146	A2	20021010	WO 2002-US6581	20020302
	WO 2002079146	A3	20030206		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2001-273206P P 20010302
US 2001-273291P P 20010302
OS MARPAT 137:295252
GI



I

AB Compds. W-(CH2)y(CR4R5)xCO-X(R1)CHR2(CHR3)r(CH2)sCO-E [X = N or CH; R1, R3 = H or alkyl; R2 = H, aryl, cycloalkyl, heteroaryl, heterocyclyl, (un)substituted alkyl or alkenyl; R1 together with R2 or R3 or R2 together with R3 form mono- or bicyclic aryl, cycloalkyl, heteroaryl, or heterocyclyl; E = (un)substituted pyrrolidino, piperidino, or

hexahydro-1-azepinyl; R4, R5 = H, (un)substituted alkyl, halo, hydroxy, amino, aryl, cycloalkyl, heterocyclyl, spirocycloalkyl ring; r, s = 0 or 1; x, y = 0-4; W = amino, carbamoyl, amidino, guanidino, heteroaryl, heterocyclyl, etc.] or their pharmaceutically-acceptable salts or prodrugs were prepd. as modulators of melanocortin receptors, particularly MC-1R and MC-4R. Thus, peptide I was prepd. by a soln.-phase peptide coupling/deprotection scheme.

IT **468105-70-6P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of peptides for pharmaceutical use as modulators of melanocortin receptors)

RN 468105-70-6 CAPLUS

CN Piperidine, 1-[(5S)-5-amino-6-(1H-imidazol-4-yl)-1,4-dioxohexyl]-4-(1-oxobutyl)-4-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2003 ACS

AN 2002:695727 CAPLUS

DN 137:226646

TI Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-AMP associated disorders

IN Macor, John E.; Carlson, Kenneth E.

PA Bristol-Myers Squibb Company, USA

SO PCT Int. Appl., 91 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002069905	A2	20020912	WO 2002-US6805	20020304
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2003069169	A1	20030410	US 2002-90258	20020304
PRAI	US 2001-273206P	P	20010302		
	US 2001-273291P	P	20010302		
	US 2001-289719P	P	20010509		

OS MARPAT 137:226646

AB Co-administration of a melanocortin receptor agonist, particularly an MC-1R or MC-4R agonist, and a cAMP phosphodiesterase inhibitor is

described for modulating levels of cyclic adenosine 3',5' monophosphate (cAMP) in a mammal. The inventive co-administration is useful in the treatment of diseases affected by activity of cAMP-PDE, including without limitation, inflammatory bowel disease, irritable bowel syndrome, rheumatoid arthritis, osteoarthritis, pancreatitis, psoriasis, migraine, Alzheimer's Disease, Parkinson's disease, transplant rejection, asthma, acute respiratory distress syndrome, chronic obstructive pulmonary disease, stroke, and neurodegeneration of, and consequences of traumatic brain injury.

IT **457894-18-7P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(Co-administration of melanocortin receptor agonist and cAMP phosphodiesterase inhibitor for treatment of cAMP-assocd. disorders)

RN 457894-18-7 CAPLUS

CN Acetamide, N-[(1S)-1-(1H-imidazol-4-ylmethyl)-2,5-dioxo-5-[4-(1-oxobutyl)-4-phenyl-1-piperidinyl]pentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.